JAMDA

New Study Published in Journal of American Medical Directors Association Highlights the BrightSpring Health Services CCRx Program for Medication Management, Including Superior Study Outcomes and a 73% Reduction in Hospitalization Rate Achieved

Retrieved on: 
Tuesday, November 21, 2023
Nursing, Health, Hospitals, Practice Management, Other Health, Managed Care, Continue, Risk management, Pharmacist, PharMerica, Patient, Insurance, Pharmacy, Journal, Medical Affairs Bureau, Health care, Quality of life, Hospital, Life, Education, JAMDA, Health insurance

Researchers hypothesized that home health patients utilizing the CCRx program may have lower hospitalization rates.

Key Points: 
  • Researchers hypothesized that home health patients utilizing the CCRx program may have lower hospitalization rates.
  • Between May 1, 2021, and March 31, 2023, 113 home health patients whose insurance covered the program were enrolled in CCRx.
  • Home health patients ineligible for the program due to a non-covered pharmacy insurance benefit made up the control group (n=21,304).
  • The successful CCRx study is another example of the very positive quality results achieved through our services and by combining BrightSpring’s home health care and medication management solutions for a better outcome.”

New Study Shows Innovative LED Lighting System Cuts Risk of Seniors Falling in Long-term Care Facilities by 43 Percent

Retrieved on: 
Thursday, August 11, 2022
Ageing, Roger Hawkins (drummer), Hospital, Public health, Risk, Division, Assistant, Population, Observational study, Circadian rhythm, Investment, Cognition, Patent, Falls, AMDA – The Society for Post-Acute and Long-Term Care Medicine, Research, Person, Intensity, Light, JAMDA, Morbidity and Mortality Weekly Report, Brigham and Women's Hospital, Patient, Alertness, Harvard Medical School, Lighting, Health care, Safety, Wisconsin Department of Children and Families, Journal, United States Patent and Trademark Office, MLI, Health, Adoption, Pharmaceutical industry, Sleep, Medicine

COTTAGE GROVE, Wis., Aug. 11, 2022 /PRNewswire/ -- A first-of-its-kind, two-year study conducted by investigators at Brigham and Women's Hospital and the Midwest Lighting Institute (MLI), showed a significant 43 percent reduction in the rate of falls in residents at long-term care facilities that utilized a tunable LED lighting system compared to control facilities that maintained standard lighting. The lighting was operated on a schedule developed by Midwest Light Institute that implements specific spectrum and intensity levels timed to regularize sleep-wake cycles and boost the daytime alerting effects of light. The results were published in the Journal of the American Medical Directors Association (JAMDA).

Key Points: 
  • Implementing new lighting systems to determine if these improvements could impact patient outcomes had not previously been evaluated in a head-to-head study.
  • The observational study examined two pairs of care homes (four sites total) with 758 residents.
  • One site from each pair was selected for a solid-state tunable lighting system upgrade throughout the facility, while the other site served as a control.
  • Midwest Lighting Institute's lighting system and its application is patented (US 11,109,467) by the United States Patent and Trademark office.

NeuroAiD(TM)II holds promise as a safe add-on therapy to standard Alzheimer Disease symptomatic treatments and may have a disease modifying effect by delaying disease progression

Retrieved on: 
Thursday, January 13, 2022
Neurodegeneration, ADAS, Patient, Dementia, Cognition, Neuroaid, Journal, Medical school, NeuroReport, Journal of the American Medical Directors Association, Brain, Department of Pharmacology, University College London, St. Luke's Hospital, Population, National University of Singapore, Ageing, Growth, DOI, Safety, American Medical Association, APP, National university, HIV disease progression rates, Alice Theadom, Department, Neuroprotection, AD, Alzheimer's disease, JAMDA, Caregiver, National University Health System, Diagnosis, Quality of life, Hospital, Associate professor, Neuropharmacology, FDA, SingHealth, Pharmaceutical industry, Residential care, Disease, Pharmacology

Current approved treatments for AD are symptomatic and do not appear to affect disease progression.

Key Points: 
  • Current approved treatments for AD are symptomatic and do not appear to affect disease progression.
  • Treatments that could effectively slow the course of AD once it has reached the clinical stage, remain an important unmet medical need.
  • The beneficial effects of NeuroAiDII on impaired cognitive functions have already been demonstrated in traumatic brain injury5.
  • The Alzheimer's disease Therapy with NEuroaid (ATHENE) Study is the first study to assess the safety and efficacy of NeuroAiDII in mild to moderate AD patients stable on standard symptomatic treatments.

NeuroAiD(TM)II holds promise as a safe add-on therapy to standard Alzheimer Disease symptomatic treatments and may have a disease modifying effect by delaying disease progression

Retrieved on: 
Thursday, January 13, 2022
Neurodegeneration, ADAS, Patient, Dementia, Cognition, Neuroaid, Journal, Medical school, NeuroReport, Journal of the American Medical Directors Association, Brain, Department of Pharmacology, University College London, St. Luke's Hospital, Population, National University of Singapore, Ageing, Growth, DOI, Safety, American Medical Association, APP, National university, HIV disease progression rates, Alice Theadom, Department, Neuroprotection, AD, Alzheimer's disease, JAMDA, Caregiver, National University Health System, Diagnosis, Quality of life, Hospital, Associate professor, Neuropharmacology, FDA, SingHealth, Health insurance, Residential care, Pharmaceutical industry, Disease, Pharmacology

Current approved treatments for AD are symptomatic and do not appear to affect disease progression.

Key Points: 
  • Current approved treatments for AD are symptomatic and do not appear to affect disease progression.
  • Treatments that could effectively slow the course of AD once it has reached the clinical stage, remain an important unmet medical need.
  • The beneficial effects of NeuroAiDII on impaired cognitive functions have already been demonstrated in traumatic brain injury5.
  • The Alzheimer's disease Therapy with NEuroaid (ATHENE) Study is the first study to assess the safety and efficacy of NeuroAiDII in mild to moderate AD patients stable on standard symptomatic treatments.

Signature HealthCARE and Genesis HealthCare Target Futuristic Goals for a Collaborative Healthcare Environment

Retrieved on: 
Tuesday, November 9, 2021
Nursing, Industry, Accreditation, Medicare, Health, Organization, Eye, Classification, Public health emergency, Great Places, Learning, Centers for Medicare & Medicaid Services, COVID-19, Negotiation, QAPI, JAMDA, AMDA – The Society for Post-Acute and Long-Term Care Medicine, Company, GLOBE, Center, Long-term care, Innovation, Journal, Communication, Genesis, Patient, District, Collaboration, Pharmaceutical industry, Medicine

But it is these challenges that conversely inspired a collaborative endeavor between two leaders in the skilled nursing industry, Signature HealthCARE and Genesis HealthCare, who together developed a framework for interprofessional collaboration during a pandemic and beyond.

Key Points: 
  • But it is these challenges that conversely inspired a collaborative endeavor between two leaders in the skilled nursing industry, Signature HealthCARE and Genesis HealthCare, who together developed a framework for interprofessional collaboration during a pandemic and beyond.
  • Signature HealthCARE and Genesis HealthCare, hope their collaboration in developing this framework is an example, catalyst, and firm foundation for a change in the landscape of collaborative healthcare, for now and in the future.
  • A growing number of Signature HealthCARE centers are earning five-star quality ratings, the highest classification from the Centers for Medicare & Medicaid Services, and 100+ Signature HealthCARE locations earned QAPI accreditation.
  • References made in this release to "Genesis," "the Company," "we," "us" and "our" refer to Genesis Healthcare, Inc. and each of its wholly-owned companies.